Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. trimmed its position in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 45.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 122,722 shares of the company's stock after selling 103,421 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.21% of Inari Medical worth $5,061,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Aigen Investment Management LP bought a new position in Inari Medical during the third quarter worth about $428,000. Vestal Point Capital LP boosted its stake in shares of Inari Medical by 342.9% in the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company's stock valued at $63,922,000 after buying an additional 1,200,000 shares during the period. Lighthouse Investment Partners LLC bought a new stake in shares of Inari Medical in the second quarter valued at approximately $2,145,000. Dynamic Technology Lab Private Ltd acquired a new stake in Inari Medical during the third quarter worth approximately $1,397,000. Finally, Integral Health Asset Management LLC increased its stake in Inari Medical by 100.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company's stock worth $19,260,000 after acquiring an additional 200,000 shares during the period. Institutional investors own 90.98% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Needham & Company LLC restated a "hold" rating on shares of Inari Medical in a research report on Tuesday, October 29th. Leerink Partners assumed coverage on Inari Medical in a research report on Tuesday, September 3rd. They set a "market perform" rating and a $47.00 price objective for the company. Leerink Partnrs upgraded Inari Medical to a "hold" rating in a research report on Tuesday, September 3rd. Truist Financial upped their price target on shares of Inari Medical from $46.00 to $50.00 and gave the stock a "hold" rating in a report on Tuesday, October 29th. Finally, Piper Sandler upped their price objective on Inari Medical from $50.00 to $52.00 and gave the company a "neutral" rating in a research note on Tuesday, October 29th. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $58.89.

Inari Medical Stock Down 0.9 %

NARI traded down $0.48 during trading on Friday, reaching $51.08. The stock had a trading volume of 809,525 shares, compared to its average volume of 667,190. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $67.13. The business has a 50-day moving average of $47.30 and a 200-day moving average of $47.72.

Insider Activity at Inari Medical

In other Inari Medical news, CFO Mitch C. Hill sold 3,000 shares of the firm's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $45.13, for a total transaction of $135,390.00. Following the sale, the chief financial officer now directly owns 179,600 shares of the company's stock, valued at $8,105,348. This trade represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William Hoffman sold 60,000 shares of the firm's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $51.16, for a total value of $3,069,600.00. Following the transaction, the director now owns 501,233 shares of the company's stock, valued at approximately $25,643,080.28. The trade was a 10.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 186,000 shares of company stock valued at $8,990,990 in the last three months. Company insiders own 10.60% of the company's stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.